564 related articles for article (PubMed ID: 21555683)
21. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.
Falini B; Martelli MP; Mecucci C; Liso A; Bolli N; Bigerna B; Pucciarini A; Pileri S; Meloni G; Martelli MF; Haferlach T; Schnittger S
Haematologica; 2008 May; 93(5):775-9. PubMed ID: 18367491
[TBL] [Abstract][Full Text] [Related]
22. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
[TBL] [Abstract][Full Text] [Related]
23. NPM1 for MRD? Droplet Like It's Hot!
Wertheim GBW; Bagg A
J Mol Diagn; 2017 Jul; 19(4):498-501. PubMed ID: 28645444
[TBL] [Abstract][Full Text] [Related]
24. A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations.
Dvorakova D; Lengerova M; Pospisilova J; Palasek I; Mayer J
Leukemia; 2009 Apr; 23(4):793-6. PubMed ID: 18830256
[No Abstract] [Full Text] [Related]
25. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
Bains A; Luthra R; Medeiros LJ; Zuo Z
Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
[TBL] [Abstract][Full Text] [Related]
26. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia.
Lo-Coco F; Cuneo A; Pane F; Cilloni D; Diverio D; Mancini M; Testoni N; Bardi A; Izzo B; Bolli N; La Starza R; Fazi P; Iacobelli S; Piciocchi A; Vignetti M; Amadori S; Mandelli F; Pelicci PG; Mecucci C; Falini B; Saglio G;
Haematologica; 2008 Jul; 93(7):1017-24. PubMed ID: 18508799
[TBL] [Abstract][Full Text] [Related]
28. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
[TBL] [Abstract][Full Text] [Related]
29. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia.
Falini B; Mecucci C; Saglio G; Lo Coco F; Diverio D; Brown P; Pane F; Mancini M; Martelli MP; Pileri S; Haferlach T; Haferlach C; Schnittger S
Haematologica; 2008 Mar; 93(3):439-42. PubMed ID: 18268276
[TBL] [Abstract][Full Text] [Related]
30. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
Pettersson L; Levéen P; Axler O; Dvorakova D; Juliusson G; Ehinger M
Genes Chromosomes Cancer; 2016 Oct; 55(10):750-66. PubMed ID: 27191933
[TBL] [Abstract][Full Text] [Related]
31. Assessment of Minimal Residual Disease in Standard-Risk AML.
Ivey A; Hills RK; Simpson MA; Jovanovic JV; Gilkes A; Grech A; Patel Y; Bhudia N; Farah H; Mason J; Wall K; Akiki S; Griffiths M; Solomon E; McCaughan F; Linch DC; Gale RE; Vyas P; Freeman SD; Russell N; Burnett AK; Grimwade D;
N Engl J Med; 2016 Feb; 374(5):422-33. PubMed ID: 26789727
[TBL] [Abstract][Full Text] [Related]
32. Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse.
Sperr WR; Mitterbauer M; Mitterbauer G; Kundi M; Jäger U; Lechner K; Valent P
Clin Cancer Res; 2005 Sep; 11(18):6536-43. PubMed ID: 16166430
[TBL] [Abstract][Full Text] [Related]
33. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
[TBL] [Abstract][Full Text] [Related]
34. Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.
Mencia-Trinchant N; Hu Y; Alas MA; Ali F; Wouters BJ; Lee S; Ritchie EK; Desai P; Guzman ML; Roboz GJ; Hassane DC
J Mol Diagn; 2017 Jul; 19(4):537-548. PubMed ID: 28525762
[TBL] [Abstract][Full Text] [Related]
35. [Analysis of NPM1 gene mutations in acute myeloid leukemia].
Yan LZ; Chen SN; Liang JY; Feng YF; Cen JN; He J; Chang WR; Zhu ZL; Pan JL; Wu YF; Xue YQ; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):289-93. PubMed ID: 17877154
[TBL] [Abstract][Full Text] [Related]
36. Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia.
Scholl S; Loncarevic IF; Krause C; Kunert C; Clement JH; Höffken K
Leuk Res; 2005 Jul; 29(7):849-53. PubMed ID: 15921740
[TBL] [Abstract][Full Text] [Related]
37. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia.
Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M
Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184
[TBL] [Abstract][Full Text] [Related]
38. Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.
Ferrara F; Izzo T; Criscuolo C; Riccardi C; Muccioli G; Viola A; Pane F; Palmieri S
Biol Blood Marrow Transplant; 2010 Jul; 16(7):1018-24. PubMed ID: 20172040
[TBL] [Abstract][Full Text] [Related]
39. Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia.
Scholl S; Mügge LO; Landt O; Loncarevic IF; Kunert C; Clement JH; Höffken K
Leuk Res; 2007 Sep; 31(9):1205-11. PubMed ID: 17306368
[TBL] [Abstract][Full Text] [Related]
40. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
